Glenmark Pharmaceuticals Inc., USA has announced the acquisition and launch of Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials. Glenmark’s Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials can be expected to have the same therapeutic effect as the listed drug product upon which the agency relied as the basis of safety and effectiveness, Acetadote Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials of Cumberland Pharmaceuticals Inc. Glenmark acquired the ANDA for Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials from Aspen Pharma USA Inc.

According to IQVIA sales data for the 12-month period ending January 2025, the Acetadote Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials market achieved annual sales of approximately USD 15.2 million.

Commenting on the launch, Marc Kikuchi, President and Business Head, North America said, “We are excited to announce the acquisition and launch of Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials. This is a great addition to our injectable portfolio in the US market as we continue to drive growth for the hospital segment.”

Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology.

The company has 11 manufacturing facilities spread across 4 continents, and operations in over 80 countries. “Glenmark’s Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this,” the company stated.